Regeneron anticipates a decline in EYLEA sales due to biosimilar competition. DUPIXENT continues to expand globally, with significant growth expected by 2030. The company is investing $7 billion ...

So, she was not there, so she should get some better information." The interview was shared on various social-media accounts, including the X account of Acyn, senior digital editor for American ...

Mineralys Therapeutics reports strong Q1 2025 results, announcing pivotal trial success for lorundrostat, a $201M equity raise, and progress toward ...

It demanded the company provide information on each affected case as well as clarify why the company “delayed two months” before notifying trustees and whether or not the company has contacted ...

Despite the challenges related to the EYLEA product line, the analyst views potential in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s long-term growth prospects. Furthermore, the Factor XI ...

Danyelza is now a recommended treatment in NCCN guidelines for relapsed or refractory high-risk neuroblastoma, a type of ...

The FDA has approved Susvimo for the treatment of people with wet AMD who have previously responded to at least two anti-VEGF drugs such as Lucentis or Bayer and Regeneron's rival Eylea (aflibercept).

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other worst ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some ...

Amgen is an innovative leader in an industry where its products will always be in high demand. Microsoft is navigating the current situation well and boasts lucrative growth opportunities. Both ...

They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months.

CEO and founder Patrick Smith said Axon Assistant ensures police officers will "have an always available voice-driven AI assistant delivering critical information exactly when and where it's ...